All Articles
In a follow-up analysis, second-line nivolumab in advanced/recurrent esophageal squamous-cell carcinoma showed significant median overall survival benefit compared with chemotherapy. Read More ›
Promising antitumor activity and a tolerable safety profile were found in patients with previously treated gastric or gastroesophageal cancer treated with trifluridine/tipiracil combined with ramucirumab. Read More ›
Insertion-deletion rate and high tumor mutation burden in advanced gastric cancer was found to be associated with favorable progression-free survival and overall survival in patients treated with nivolumab. Read More ›
Treatment with surufatinib in combination with toripalimab is associated with promising responses and manageable adverse events in previously treated gastric or gastroesophageal junction adenocarcinoma. Read More ›
Post-hoc analysis of the CheckMate-032 study found PD-L1 expression by combined positive score was more closely associated with nivolumab and ipilimumab therapy efficacy compared with percentage of positive tumor cells PD-L1 expression in advanced gastric/gastroesophageal junction cancer. Read More ›
Progression-free survival and overall survival improved more after treatment with ramucirumab plus paclitaxel compared with placebo plus paclitaxel in Asian patients with advanced gastric and gastroesophageal junction cancer who were previously treated with chemotherapy. Read More ›
Progression-free survival and overall survival improved more after treatment with ramucirumab plus paclitaxel compared with placebo plus paclitaxel in Asian patients with advanced gastric and gastroesophageal junction cancer who were previously treated with chemotherapy. Read More ›
Nivolumab with paclitaxel plus ramucirumab as second-line therapy in patients with advanced gastric cancer demonstrated promising responses with manageable treatment-related adverse events. Read More ›
By William King
Oncologic drug pricing is being transformed with greater value in mind. At the 11th Annual Summit of the Association for Value-Based Cancer Care in 2021, a panel led by moderator William McGivney, PhD, Managing Principal, McGivney Global Advisors, Wayne, PA, discussed innovation in drug pricing, how the current rebate system supports higher drug costs, balancing new interventions with profits, and the implications of drug price negotiations being considered in Congress. Read More ›
Pharmacy benefit managers (PBMs) have developed a new approach to marketing themselves as stewards of the self-funded employers’ healthcare benefit, and it is having direct negative consequences for patients. Under the alternate funding program, new or costly therapies used to treat serious and chronic conditions, including cancer, are being singled out. Read More ›